What I was taking about is Immune response Assessment of treatment. Today, we don’t have to wait years to see if the treatment is working. The most recent clinical trials are;
* Analyzing blood samples to evaluate the patient's immune response to the vaccine.
* Measuring the levels of specific immune cells, such as T cells, and assessing their ability to recognize and attack tumor cells.
* Evaluating the presence of specific antibodies that attack the tumor.
* Analyzing T-cell responses:
* Because DCVax-L is a immunotherapy, a large part of the monitoring involves seeing if the patients T-cells are responding to the glioblastoma.
I was also talking about Combination trials with DCVax-L.
A lot has changed in the last 3 years.
But somehow you thought I was talking about mRNA vaccines?